Ligand Pharmaceuticals (LGND) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $298.50, +1.19% vs the prior close of $294.99.
- Volume 332.10K shares, 1.4x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
LGND rises 1.2% to $298.50. Closed at $298.50, +1.19% vs the prior close of $294.99. Day range $296.85–$304.60, opened at $298.18.
LGND daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — LGND rises 1.2% to $298.50
- Closed at $298.50, +1.19% vs the prior close of $294.99. Day range $296.85–$304.60, opened at $298.18.
- Volume was 332.10K shares, 1.4x its 50-day average of 238.64K.
- Price is +2.0% vs its 50-day average ($292.54) and +21.1% vs its 200-day average ($246.42).
- 52-week range $175.89–$326.63; today's close sits at 81% of that range, 8.6% below the 52-week high.
Oct 14, 2026 — LGND dips 2.8% to $294.99
- Closed at $294.99, -2.81% vs the prior close of $303.53. Day range $292.28–$307.11, opened at $299.55.
- Volume was 245.30K shares, 1.0x its 50-day average of 240.32K.
- Price is +0.8% vs its 50-day average ($292.63) and +20.0% vs its 200-day average ($245.90).
- 52-week range $175.89–$326.63; today's close sits at 79% of that range, 9.7% below the 52-week high.
Oct 13, 2026 — LGND dips 2.4% to $303.53
- Closed at $303.53, -2.44% vs the prior close of $311.13. Day range $300.23–$311.72, opened at $311.72.
- Volume was 196.60K shares, 0.8x its 50-day average of 240.22K.
- Price is +3.7% vs its 50-day average ($292.74) and +23.7% vs its 200-day average ($245.40).
- 52-week range $175.89–$326.63; today's close sits at 85% of that range, 7.1% below the 52-week high.
Oct 12, 2026 — LGND jumps 3.1% to $311.13, 3 up days in a row
- Closed at $311.13, +3.09% vs the prior close of $301.81. Day range $300.00–$311.86, opened at $302.50.
- Volume was 173.20K shares, 0.7x its 50-day average of 242.20K.
- Price is +6.4% vs its 50-day average ($292.51) and +27.1% vs its 200-day average ($244.87).
- 52-week range $175.89–$326.63; today's close sits at 90% of that range, 4.7% below the 52-week high.
- That makes 3 straight gains.
Oct 9, 2026 — LGND rises 2.3% to $301.81
- Closed at $301.81, +2.31% vs the prior close of $295.00. Day range $294.32–$304.78, opened at $294.79.
- Volume was 183.00K shares, 0.7x its 50-day average of 244.21K.
- Price is +3.3% vs its 50-day average ($292.04) and +23.5% vs its 200-day average ($244.30).
- 52-week range $175.89–$326.63; today's close sits at 84% of that range, 7.6% below the 52-week high.
Oct 8, 2026 — LGND rises 0.6% to $295.00
- Closed at $295.00, +0.59% vs the prior close of $293.26. Day range $281.74–$296.48, opened at $290.41.
- Volume was 318.90K shares, 1.3x its 50-day average of 244.96K.
- Price is +1.1% vs its 50-day average ($291.93) and +21.0% vs its 200-day average ($243.78).
- 52-week range $175.89–$326.63; today's close sits at 79% of that range, 9.7% below the 52-week high.
Oct 7, 2026 — LGND dips 1.2% to $293.26
- Closed at $293.26, -1.24% vs the prior close of $296.94. Day range $292.47–$301.27, opened at $293.63.
- Volume was 309.20K shares, 1.3x its 50-day average of 245.85K.
- Price is +0.5% vs its 50-day average ($291.79) and +20.5% vs its 200-day average ($243.31).
- 52-week range $175.89–$326.63; today's close sits at 78% of that range, 10.2% below the 52-week high.
Oct 6, 2026 — LGND slides 3.2% to $296.94
- Closed at $296.94, -3.20% vs the prior close of $306.77. Day range $293.73–$309.41, opened at $309.41.
- Volume was 163.70K shares, 0.7x its 50-day average of 250.14K.
- Price is +1.7% vs its 50-day average ($291.85) and +22.3% vs its 200-day average ($242.84).
- 52-week range $175.89–$326.63; today's close sits at 80% of that range, 9.1% below the 52-week high.
Oct 5, 2026 — LGND rises 1.3% to $306.77
- Closed at $306.77, +1.26% vs the prior close of $302.96. Day range $300.79–$309.77, opened at $303.95.
- Volume was 163.80K shares, 0.6x its 50-day average of 252.41K.
- Price is +5.1% vs its 50-day average ($291.86) and +26.6% vs its 200-day average ($242.32).
- 52-week range $175.89–$326.63; today's close sits at 87% of that range, 6.1% below the 52-week high.
Oct 2, 2026 — LGND ends flat (+0.1%) to $302.96
- Closed at $302.96, +0.07% vs the prior close of $302.74. Day range $301.32–$307.63, opened at $307.55.
- Volume was 179.20K shares, 0.7x its 50-day average of 255.93K.
- Price is +3.8% vs its 50-day average ($291.74) and +25.3% vs its 200-day average ($241.75).
- 52-week range $175.56–$326.63; today's close sits at 84% of that range, 7.2% below the 52-week high.
LGND latest news & SEC filings
Every SEC filing by or about LGND in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Reardon Andrew converted options/RSUs into 340 shares at $52.27 (≈$17.77K) on Oct 2, 2026; now holds 36,854
- Reardon Andrew sold 833 shares at $302.51 (≈$251.99K) on Oct 2, 2026; now holds 36,021
- Reardon Andrew sold 1,976 shares at $303.54 (≈$599.80K) on Oct 2, 2026; now holds 34,045
- Reardon Andrew sold 1,535 shares at $304.52 (≈$467.43K) on Oct 2, 2026; now holds 32,510
- Reardon Andrew sold 404 shares at $306.18 (≈$123.70K) on Oct 2, 2026; now holds 32,106
- Reardon Andrew sold 235 shares at $307.19 (≈$72.19K) on Oct 2, 2026; now holds 31,871
- …plus 1 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Zimmermann Martine had withheld for taxes 115 shares at $298.50 (≈$34.33K) on Sep 22, 2026; now holds 3,782
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Zimmermann Martine sold 1,200 shares at $285.00 (≈$342.00K) on Sep 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 10, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Reardon Andrew sold 385 shares at $287.53 (≈$110.70K) on Sep 3, 2026
- Reardon Andrew sold 1,800 shares at $285.17 (≈$513.31K) on Sep 3, 2026
- Reardon Andrew sold 2,115 shares at $286.36 (≈$605.65K) on Sep 3, 2026
- Reardon Andrew sold 300 shares at $283.99 (≈$85.20K) on Sep 3, 2026
- Reardon Andrew sold 400 shares at $288.98 (≈$115.59K) on Sep 3, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 3, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 2, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Exhibits / financial statements only (Item 9.01).
Aug 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $63.69M (prior year $47.63M) (+33.7% vs Jun 30, 2025)
- Net income: $48.51M (prior year $4.85M) (+900.8% vs Jun 30, 2025)
- Diluted EPS: $2.22 (prior year $0.24) (+825.0% vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 22, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Jul 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.01 — Completed an acquisition or sale of assets.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jun 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade LGND
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.70% (largest 4.2%).
- Liquidity: about 274.58K shares (≈$81.96M) trade per day on average.
- 52-week position: $298.50 vs a range of $175.89–$326.63 (81% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Martine Zimmermann sold 1,200 shares on Sep 10, 2026.
- Latest filings: 8-K Sep 24, 2026; 8-K Sep 22, 2026; 10-Q Aug 7, 2026.
- Share count: 19.94M shares outstanding (Aug 4, 2026), +1.7% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
LGND market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 298.18 | 304.60 | 296.85 | 298.50 | 332.10K |
| Oct 14, 2026 | 299.55 | 307.11 | 292.28 | 294.99 | 245.30K |
| Oct 13, 2026 | 311.72 | 311.72 | 300.23 | 303.53 | 196.60K |
| Oct 12, 2026 | 302.50 | 311.86 | 300.00 | 311.13 | 173.20K |
| Oct 9, 2026 | 294.79 | 304.78 | 294.32 | 301.81 | 183.00K |
| Oct 8, 2026 | 290.41 | 296.48 | 281.74 | 295.00 | 318.90K |
| Oct 7, 2026 | 293.63 | 301.27 | 292.47 | 293.26 | 309.20K |
| Oct 6, 2026 | 309.41 | 309.41 | 293.73 | 296.94 | 163.70K |
| Oct 5, 2026 | 303.95 | 309.77 | 300.79 | 306.77 | 163.80K |
| Oct 2, 2026 | 307.55 | 307.63 | 301.32 | 302.96 | 179.20K |
| Oct 1, 2026 | 309.82 | 312.05 | 301.48 | 302.74 | 374.00K |
| Sep 30, 2026 | 310.52 | 317.23 | 306.95 | 312.37 | 505.90K |
| Sep 29, 2026 | 313.63 | 317.10 | 304.36 | 310.36 | 431.00K |
| Sep 28, 2026 | 299.78 | 314.94 | 299.70 | 314.10 | 239.60K |
| Sep 25, 2026 | 303.17 | 305.35 | 293.90 | 301.52 | 305.80K |
| Sep 24, 2026 | 296.95 | 303.41 | 296.37 | 299.04 | 209.40K |
| Sep 23, 2026 | 300.44 | 302.44 | 296.08 | 298.41 | 242.00K |
| Sep 22, 2026 | 291.00 | 300.48 | 289.00 | 298.50 | 308.70K |
| Sep 21, 2026 | 283.67 | 290.51 | 282.45 | 290.07 | 237.40K |
| Sep 18, 2026 | 285.63 | 285.64 | 280.49 | 283.49 | 372.80K |
About Ligand Pharmaceuticals
Ligand Pharmaceuticals (LGND) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 886163.
LGND board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jason Aryeh | Director | Jun 12, 2026 |
| Todd C Davis | Chief Executive Officer | Jul 6, 2026 |
| Nancy Ryan Gray | Director | Jun 9, 2026 |
| Jason Haas | Director | Aug 14, 2026 |
| John W Kozarich | Director | Jun 9, 2026 |
| John L Lamattina | Director | Jun 12, 2026 |
| Stephen L Sabba | Director | Jun 18, 2026 |
| Martine Zimmermann | Director | Sep 24, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Todd C Davis | Chief Executive Officer | Jul 6, 2026 |
| Octavio Espinoza | Chief Financial Officer | Aug 14, 2026 |
| Andrew Reardon | CLO & Secretary | Sep 8, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 10, 2026 | Martine Zimmermann | Sale | 1,200 | $285.00 |
| Sep 3, 2026 | Andrew Reardon | Sale | 385 | $287.53 |
| Sep 3, 2026 | Andrew Reardon | Sale | 1,800 | $285.17 |
| Sep 3, 2026 | Andrew Reardon | Sale | 2,115 | $286.36 |
| Sep 3, 2026 | Andrew Reardon | Sale | 300 | $283.99 |
| Sep 3, 2026 | Andrew Reardon | Sale | 400 | $288.98 |
| Aug 12, 2026 | Octavio Espinoza | Sale | 31,641 | $292.07 |
| Aug 12, 2026 | Jason Haas | Sale | 7,138 | $292.81 |
| Aug 3, 2026 | Andrew Reardon | Sale | 200 | $290.60 |
| Aug 3, 2026 | Andrew Reardon | Sale | 991 | $291.71 |
| Aug 3, 2026 | Andrew Reardon | Sale | 409 | $292.82 |
| Aug 3, 2026 | Andrew Reardon | Sale | 105 | $284.14 |
| Aug 3, 2026 | Andrew Reardon | Sale | 33 | $284.55 |
| Aug 3, 2026 | Andrew Reardon | Sale | 157 | $285.74 |
| Aug 3, 2026 | Andrew Reardon | Sale | 1,032 | $286.80 |
LGND financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $268.09M | $124.45M | 6.13 | $49.36M |
| Dec 31, 2024 | $167.13M | $-4.03M | -0.22 | $97.05M |
| Dec 31, 2023 | $131.31M | $52.15M | 2.94 | $49.58M |
| Dec 31, 2022 | $196.25M | $-33.36M | -1.98 | $137.85M |
| Dec 31, 2021 | $241.54M | $57.14M | 3.31 | $78.80M |
Latest balance sheet: total assets $2.19B, total liabilities $1.22B, cash $1.01B (as of Jun 30, 2026).
LGND earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $300.14 |
| May 7, 2026 | 8-K Item 2.02 (results) | $210.33 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $196.17 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $208.22 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $146.32 |
| May 8, 2025 | 8-K Item 2.02 (results) | $102.51 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $115.67 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $129.90 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2024 | 8-K Item 2.02 (results) | — |
| Nov 8, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on LGND
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.